Publications by authors named "M T Vijayalakshmi"

Checkpoint kinase 1 (Chk-1), a serine/threonine kinase family protein, is an emerging target in cancer research owing to its crucial role in cell cycle arrest. Therefore, we aimed to predict potential Chk-1 inhibitors from Momordica charantia Linn., using high-throughput molecular docking.

View Article and Find Full Text PDF

Neuro-immune dysfunction and inflammation are said to be involved in the aetiology of major mental illnesses. This study describes the assessment of the protease-like catalytic function of serum IgG in psychiatric disorders, schizophrenia and bipolar disorder, along with healthy controls of Indian ethnicity. Systemic lupus erythematosus patients experiencing neuropsychiatry conditions were included as comparators for the comprehensive evaluation of IgG catalytic function.

View Article and Find Full Text PDF
Article Synopsis
  • * The goal is to create a fish detection system in ponds to enhance small-scale aquaculture through non-invasive methods, focusing on species like Orange Chromide (Etroplus maculatus).
  • * The dataset contains annotated images from underwater videos captured in Retteri Pond, designed to assist aquaculture and computer vision experts in developing automated fish detection tools.
View Article and Find Full Text PDF
Article Synopsis
  • Extensive use of fossil fuels leads to high CO2 emissions, necessitating the development of eco-friendly energy storage materials.
  • Hybrid supercapacitors (HSCs) are emerging materials that provide quick charging and high capacitance retention, with the current study focusing on a composite of g-CN nanosheets and CoO/CeO heterostructures as effective electrodes.
  • The CoCe/g-CN electrodes demonstrate significantly higher specific capacitance (1088.3 F/g) and impressive stability (96% over 5000 cycles), making them promising options for advanced energy storage solutions.
View Article and Find Full Text PDF

Coagulation factor replacement therapy for the X-linked bleeding disorder Haemophilia, characterized by a deficiency of coagulation protein factor VIII (FVIII), is severely complicated by antibody (inhibitors) formation. The development of FVIII inhibitors drastically alters the quality of life of the patients and is associated with a tremendous increase in morbidity as well as treatment costs. The ultimate goal of inhibitor control is antibody elimination.

View Article and Find Full Text PDF